Drug intelligence / Profile preview

TQ-1020

Development stage: Preclinical
Lead developer: TheraQuest Biosciences
Modality: Small Molecules
Administration: Oral

Overview

**TQ-1020** is a proprietary once-daily extended-release formulation of the opioid analgesic levorphanol, designed with an abuse-deterrent drug delivery system to reduce misuse potential. Levorphanol acts as a mu-opioid receptor agonist, providing potent analgesia for moderate to severe pain through central nervous system depression and modulation of pain pathways. Developed by TheraQuest Biosciences for chronic pain management, it aims to offer sustained pain relief while minimizing risks associated with traditional opioids, such as abuse, diversion, and accidental overdose.

Other names: Levorphanol Extended Release

Targets

KOR (Kappa opioid receptor)MAT (Monoamine transporters)MOR (Mu opioid receptor)DOR (Opioid Receptor Delta 1)

Beyond the preview

Go deeper on TQ-1020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TQ-1020.

Explore the full profile